Safety and Effectiveness of Botulinum Toxin in Elderly Patients With Dementia and Muscle Stiffness
- Registration Number
- NCT02212119
- Lead Sponsor
- Assistive Technology Clinic, Canada
- Brief Summary
Aim of the study is to perform a pilot study to assess the impact of Botulinum toxin on muscle tone, and caregiver burden in individuals who are cognitively impaired and who are fully dependent.
The primary objective is to confirm proof of principle that paratonic rigidity and the consequences associated with it can be reduced with injection of Botulinum toxin injections resulting in reduced care-giver burden.
The secondary objectives are to determine optimal time points for evaluation of efficacy in this patient population and whether the time period is sufficient for washout of Botulinum toxin effect; determine most salient and sensitive outcome measures; identify obstacles in data gathering; and lastly, to determine feasibility of battery of assessments in this pilot study.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 10
- Severe cognitive impairment (complete dependency in all activities of daily living (ADLs)
- Diagnosis of Alzheimer's disease, vascular dementia,or frontotemporal dementia
- Score> 3 on the paratonic assessment instrument, with paratonic rigidity in an arm(s) interfering in the provision of care
- Alternate etiologies for increased tone
- Botulinum toxin 6 months preceding the study
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Saline Saline Saline injection up to 5 cc in arm with paratonia (one time injection) Botulinum Toxin Botulinum Toxin Up to 300 U (5 cc) of Botulinum toxin diluted 2:1 (2 cc per 100 U of Botulinum toxin) (one time injection)
- Primary Outcome Measures
Name Time Method Impact on care-giver burden 6 weeks for primary outcome, 32 weeks for entire study Impact on caregiver burden in providing upper extremity care.
Measured by the Carer Burden Scale which includes four items (cleaning the palm, cutting the fingernails, dressing, cleaning under the armpit).
Each item rated on five point Likert scale ("no difficulty" to "cannot do task").
- Secondary Outcome Measures
Name Time Method Pain 6 weeks for secondary outcome, 32 weeks for entire study Pain Assessment in Advanced Dementia (PAINAD) Scale used to evaluate correlates of pain and determine whether Botulinum toxin treatment reduces discomfort of morning care.
Consists of 5 items (breathing, negative vocalization, facial expression, body language and consolability), scored on a 0-2 point scale and then summed to arrive at a total scale.Joint angle measurement 6 weeks for secondary outcome, 32 weeks for entire study Joint angle measurements were used reflecting range of motion.
Used as a surrogate measure for severity of paratoniaGlobal Assessment 6 weeks for secondary outcome, 32 weeks for entire study Overall response to treatment evaluated by study investigator and by professional caregiver caring for patient using the global assessment scale.
A score of -4 indicates very marked worsening, 0 no change, and +4 very marked improvement.Visual Analogue Scale 6 weeks for secondary outcome, 32 weeks for entire study Completed by the professional caregiver that is caring for the patient to assess perception of ease of caregiving.
Consists of 100 mm line with anchors of 0 "giving care to the residents is very difficult" and 100 "giving care to the residents is very easy"
Trial Locations
- Locations (1)
Assistive Technology Clinic at Baycrest
🇨🇦Toronto, Ontario, Canada